Guo Yu, Xu Yong-Gang, Liu Chao, Zhang Heng-Zhu, Luo Wenmiao
Department of Neurosurgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Department of Neurosurgery, Xiamen Susong Hospital, Xiamen, China.
J Neurointerv Surg. 2025 Jun 1;17(e2):e222-e230. doi: 10.1136/jnis-2024-021958.
This study investigates the efficacy and safety of bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT) compared with EVT alone in patients with large infarction core.
We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library from January 2015 to June 2024. Included studies involved patients with acute ischemic stroke with an Alberta Stroke Program Early CT Score of ≤5 or an ischemic core volume of ≥50 mL. Studies were required to provide either 90-day modified Rankin Scale (mRS) score, reperfusion, symptomatic intracranial hemorrhage (sICH), or 90-day mortality.
Nine observational studies with 2641 patients were analyzed. The IVT+EVT group had a higher rate of 90-day functional independence (mRS 0-2; OR 1.56, 95% CI 1.31 to 1.87; adjusted OR (aOR) 1.43, 95% CI 1.21 to 1.68) and 90-day functional outcome (mRS 0-3; OR 1.34, 95% CI 1.11 to 1.62; aOR 1.18, 95% CI 1.02 to 1.37) compared with EVT alone. There was no significant difference in successful reperfusion (OR 1.01, 95% CI 0.62 to 1.64; aOR 1.07, 95% CI 0.74 to 1.54) and 90-day mortality (OR 0.86, 95% CI 0.73 to 1.02; aOR 0.89, 95% CI 0.77 to 1.04) between the two groups. Moreover, patients who received IVT+EVT had a higher rate of sICH (OR 1.30, 95% CI 1.03 to 1.64; aOR 2.21, 95% CI 1.22 to 4.01).
In patients with large infarction core, bridging IVT before EVT is associated with favorable functional outcomes compared with EVT, even though bridging therapy entails a higher risk of sICH. Further trials are needed to confirm these findings.
本研究旨在探讨在大梗死核心患者中,血管内治疗(EVT)前桥接静脉溶栓(IVT)与单纯EVT相比的疗效和安全性。
我们对2015年1月至2024年6月期间的PubMed、EMBASE和Cochrane图书馆进行了全面检索。纳入的研究涉及阿尔伯塔卒中项目早期CT评分≤5或缺血核心体积≥50 mL的急性缺血性卒中患者。研究需提供90天改良Rankin量表(mRS)评分、再灌注情况、症状性颅内出血(sICH)或90天死亡率。
分析了9项观察性研究,共2641例患者。与单纯EVT组相比,IVT+EVT组90天功能独立率(mRS 0-2;OR 1.56,95%CI 1.31至1.87;调整后OR(aOR)1.43,95%CI 1.21至1.68)和90天功能结局(mRS 0-3;OR 1.34,95%CI 1.11至1.62;aOR 1.18,95%CI 1.02至1.37)更高。两组在成功再灌注(OR 1.01,95%CI 0.62至1.64;aOR 1.07,95%CI 0.74至1.54)和90天死亡率(OR 0.86,95%CI 0.73至1.02;aOR 0.89,95%CI 0.77至1.04)方面无显著差异。此外,接受IVT+EVT的患者sICH发生率更高(OR 1.30,95%CI 1.03至1.64;aOR 2.21,95%CI 1.22至4.01)。
在大梗死核心患者中,与单纯EVT相比,EVT前桥接IVT与更好的功能结局相关,尽管桥接治疗会增加sICH风险。需要进一步的试验来证实这些发现。